CME: Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting
ACCREDITATION EXPIRED: December 11, 2022
Activity Description / Statement of Need:
In this online CME self-learning program:
Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.
Target Audience:
Healthcare professionals including: medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.
This program is supported by educational grants from AMGEN.
Learners may participate in this activity free of charge.
Release Date: December 11, 2020 -- Expiration Date: December 11, 2022
Faculty: George Fisher, MD, PhD
Agenda
Faculty member introduction, disclosures, overview of colorectal
cancer
Major findings from ASCO 2020, including clinical trial data relevant
to both community and health-system practice and recognized
barriers to implementing those findings in practice
Patient cases
Concluding remarks
Learning Objectives
By the end of the session the participant will be able to:
- Understand what molecular tests should be ordered when treating patients with metastatic colorectal cancer.
- Learn how treatments directed to specific molecular features of metastatic colon cancer can influence outcomes and provide more favorable outcomes.
- Appreciate the more favorable adverse event profiles when comparing immunotherapy with chemotherapy for MSI patients and for the use of a two drug regimen versus a 3 drug regimen for BRAF V600E mutated tumors.
Accreditation
ACCME Activity #201540534
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: George Fisher MD, PhD, Stanford University, has received consulting honoraria from Merck, Terumo, Avanced Accelerator Applications. He has also received research/data safety grant support from AstraZeneca, Silensee, Roche/Genetech, Adurono, and Fourty-seven.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Treating Oncology Patients During COVID-19
Advanced prostate cancer: Optimizing management strategies
Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments